ecrin-mdr-crcClinical2013IPD Sharing (as of March 2018): UndecidedMetastatic Colorectal CancerColorectal CancerColorectal NeoplasmsMetastatic colorectal cancerMetastasesMetastatic Colorectal CancerColorectal CancerColorectal NeoplasmsMetastasesInterventionalhttps://newmdr.ecrin.org/Study/2149795Netherlands12CapecitabineHand-foot syndromeS1TeysunoFluoropyrimidineBevacizumabECRIN MDRCompletedfalseS-1 Versus Capecitabine in the First Line Treatment of MCC Patients.The study is a two-arm randomised phase III trial. Patients will be randomised to receive capecitabine (arm A) or S-1 (arm B). Bevacizumab may be added according to the choice of the investigator. Patients will be followed 3-weekly at the outpatient clinic, toxicity will be assessed according to study protocol guidelines. Patients will be evaluated every 3 cycles for response. Upon disease progression patients will be treated according to the local investigators2013-12-152149795NCT019188522013-002147-28